Navigation Links
Anti-aging cosmetic reduced wrinkles in clinical trial
Date:4/28/2009

Scientists testing a cosmetic anti-ageing product sold on the high street have shown it can clinically reduce wrinkles and improve the appearance of skin damaged by everyday exposure to sunlight.

Dermatologists at The University of Manchester carried out a clinical trial on 60 volunteers with typical signs of sun-damaged skin and found that the cosmetic, No7 Protect & Perfect Intense Beauty Serum, could improve some of these clinical features.

The study, published online in the British Journal of Dermatology today (Tuesday, April 28), showed that 70% of individuals using the beauty product had significantly fewer wrinkles after 12 months of daily use compared to volunteers using a placebo.

The research team, headed by Professor of Dermatology Chris Griffiths, reported last year that the original No7 Protect & Perfect Beauty Serum stimulated the production of fibrillin-1, a protein that promotes elasticity in the skin.

For this latest, year-long study, the researchers first wanted to discover whether the new No7 Protect & Perfect Intense Beauty Serum also promoted fibrillin-1 production but also wished to test whether this would result in a reduction in wrinkles, as has been demonstrated with prescription retinoids.

"Very few over-the-counter cosmetic 'anti-ageing' products have been subjected to a rigorous, scientific trial to prove their effectiveness," said Professor Griffiths, who is based in the University's School of Translational Medicine at Salford Royal Foundation Hospital.

"Although prescription retinoids can have a reparative effect on photo-aged skin, there is scant evidence that any of the plethora of cosmetic 'anti-ageing' products can produce similar effects."

The clinical trial funded by Boots, the makers of the No7 product range was carried out using standard scientific protocols. Having established that the No7 Protect & Perfect Intense Beauty Serum did increase fibrillin-1 production, 60 volunteers 11 men and 49 women aged 45 to 80 years were recruited to test its efficacy.

The No7 Protect & Perfect Intense Beauty Serum and a control formulation containing no anti-ageing ingredients were supplied in identical, coded packages, so neither investigators nor volunteers were aware as to the treatment of each individual. Thirty volunteers were assigned the No7 Protect & Perfect Intense Beauty Serum and 30 used the placebo formulation.

"Our findings demonstrate that a commercially-available cosmetic can produce significant improvement in the appearance of facial wrinkles following long-term use," said Professor Griffiths.

"It is rare for such benefits to be reported for an over-the-counter anti-ageing product and this study paves the way for larger studies with more statistical power."


'/>"/>

Contact: Aeron Haworth
aeron.haworth@manchester.ac.uk
44-161-275-8383
University of Manchester
Source:Eurekalert

Related medicine news :

1. Expose on Crimes Against Humanity as Perpetrated by the Gerontological Elite Asks Is Consensus in Anti-Aging Medical Intervention An Elusive Expectation or A Realistic Goal?
2. Perlabella Introduces a Highly Concentrated and Affordable Anti-Aging Skin Care Line
3. Glissandra Skincare Inc. Launches Website Showcasing New and Novel Anti-Aging Skincare Products
4. DNA Jewel to Finance Anti-Aging Services & Cancer Research
5. Anti-Aging Miracle Physicians Have Been Waiting for is Finally Here : Free Book Available From Natural Health News Report Reveals the Secret to Staying Young
6. Happy Birthday, StriVectin! The Skin Cream that Revolutionized the Anti-Aging Market
7. Zannos Grekos, MD to Present Clinical Results of Regenerative Stem Cell Treatments to the Dubai Congress on Anti-Aging and Aesthetic Medicine
8. Science Fiction Has Become Reality with Remarkable Anti-Aging Treatment Breakthrough - Turning Back the Biological Clock in Aging
9. Anti-Aging Expo & Symposium Crowns a Personal Journey to Wellness
10. AMDLs Goodnak(R) Anti-Aging Skin Care Line Soon Available in Capsule & Lotion Form
11. Dr. William S. Gruss, M.D., Says That Medical Research Shows You Can Reduce Your Risk of Cancer By Up To 77% and Reverse the Effects of Aging in A CARDIOLOGISTS GUIDE TO ... ANTI-AGING, ANTIOXIDANTS & RESVERATROL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... 20, 2017 , ... Researchers at the University of Pittsburgh School of Medicine ... that may predict response to a particular class of drugs, not just in patients ... The new findings were published in Proceedings of the National Academy of Science. , ...
(Date:2/20/2017)... , ... February 20, 2017 , ... ... regulated industries, announced Biscom Document Router (BDR), the first IoT device from Biscom ... diagnostics and imaging. Biscom will debut BDR at HIMSS17 and will ...
(Date:2/20/2017)... , ... February 20, 2017 , ... ReportingMD, a Population Health Software Company, is pleased ... the company. The new location will triple the size of the previous location while ... town of Sunapee, NH. , “We are excited to expand our footprint to ...
(Date:2/20/2017)... ... ... Chuck E. Cheese’s® and Center for Autism and Related Disorders (CARD) recently announced ... throughout New England, New York and New Jersey to provide children with autism spectrum ... Chuck E. Cheese’s in a sensory-friendly environment. , After a successful pilot run ...
(Date:2/19/2017)... , ... February 19, 2017 , ... The Citadel’s new ... nursing students, is being led by Amelia Joseph, Ph.D. Joseph was engaged by the ... of the nursing department in early 2016. After a nation-wide search, she was selected ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... Lexmark International, ... solution that connects Lexmark multifunction printers (MFPs) to EDCO ... leading scanning and indexing software solutions for medical records. ... use a Lexmark MFP at the point of care ... facilities reach HIMSS Stage 7 through state-of-the-art ...
(Date:2/21/2017)... IDAHO FALLS, Idaho , Feb. 21, 2017 /PRNewswire/ ... is has completed a private placement with certain investors ... preferred stock of the Company, Series C Convertible Redeemable ... Stock accrues dividends at an annual rate of 6% ... share.  The Company plans to use the proceeds for ...
(Date:2/21/2017)... SAN JOSE, Calif. , Feb. 21, 2017 ... announced that its Cadence ® Tensilica ® Fusion ... HaLow ™ MAC IP offering. The licensable IP targets ... smart city and industrial applications. M2B leveraged the Fusion F1 ... to run value-added applications like voice trigger, audio identification and ...
Breaking Medicine Technology: